Vasa Therapeutics
MMP-2/MMP-9 inhibitors for cardiac fibrosis
Privately held: no public share price · United States
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | MMP-2/MMP-9Small molecule | Heart Failure |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
12 November 2026Topline resultVasa Therapeutics VS-041Phase 1c HFpEF trial reports positive topline results
Vasa Therapeutics · Source ↗
Financial reports
No financial reports recorded.